EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data

Tamino Zappalà iD, Anton Pottegård iD, Carola A Huber iD, Daphne Reinau iD, Christoph R Meier iD, Julia Spoendlin iD

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.70005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Tamino Zappalà und 5 weiteren Autor:innen. Beteiligte Einrichtung: Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, S…. Hauptthemen laut MEDLINE: Hydrochlorothiazide, Antihypertensive Agents, Interrupted Time Series Analysis, Skin Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basel Pharmacoepidemiology Unit (BPU).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Long‐term use of hydrochlorothiazide increases the risk of non‐melanoma skin cancer. We aimed to evaluate potential changes in the use of hydrochlorothiazide in Switzerland after a direct healthcare professional communication (DHPC) in November 2018 by Swissmedic.

Methods

We performed interrupted time‐series analyses using a large Swiss healthcare claims database (2015–2021). Within monthly intervals, we quantified the total number of claims and the total dispensed ‘defined daily doses’ (DDD) for preparations containing (1) hydrochlorothiazide, (2) angiotensin‐converting enzyme (ACE) inhibitors and angiotensin‐II‐receptor blockers (ARB), (3) calcium‐channel blockers (CCB) and (4) thiazide‐like diuretics per 10 000 persons. Using segmented linear regression, we quantified the pre‐DHPC trend, the immediate change and the post‐DHPC change in trend for total claims and DDD for the four drug classes weighted for the demographic distribution of the Swiss population.

Results

ACE inhibitors and ARB were the most frequently claimed antihypertensive drugs with 300–400 claims per 10 000 persons, which increased by 5.4% during the study period. The average number of hydrochlorothiazide claims (157/10 000 persons in 2015) declined by 35% between 2015 and 2021. The decrease started prior to the DHPC, but the DHPC was associated with an immediate 6.1% decline and an accelerated decline in claims over time after the DHPC (similar results for DDD). This coincided with a 23% increase in claims of CCB (dihydropyridine type) over 7 years, whereas use of other antihypertensives increased less.

Conclusion

Our results suggest that the DHPC by Swissmedic in 2018 accelerated a pre‐existing decline in the use of hydrochlorothiazide in Switzerland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrochlorothiazideAntihypertensive AgentsInterrupted Time Series AnalysisSkin NeoplasmsHumansSwitzerlandMaleFemaleMiddle AgedAgedDatabases, FactualAdultAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHypertension

Stichwörter der Autor:innen

Swissmedicdirect healthcare professional communicationdrug utilisation studyhydrochlorothiazidenon‐melanoma skin cancer

Substanzen

HydrochlorothiazideAntihypertensive AgentsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Department of Health Sciences, Helsana Group, Zurich, Switzerland.
  • Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.

ORCID-Profile: Tamino Zappalà, Anton Pottegård, Carola A Huber, Daphne Reinau, Christoph R Meier, Julia Spoendlin

Förderung

  • Basel Pharmacoepidemiology Unit (BPU)

Zitieren

APA

Zappalà, T., Pottegård, A., Huber, C. A., Reinau, D., Meier, C. R., & Spoendlin, J. (2024). Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70005

Vancouver

Zappalà T, Pottegård A, Huber CA, Reinau D, Meier CR, Spoendlin J. Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70005

BibTeX
@article{Zappal2024,
  author = {Zappalà, Tamino and Pottegård, Anton and Huber, Carola A and Reinau, Daphne and Meier, Christoph R and Spoendlin, Julia},
  title = {Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.70005}
}
Kostenlos starten →